Literature DB >> 10591876

Role of estradiol in puerperal psychosis.

A Ahokas1, M Aito.   

Abstract

RATIONALE: Postpartum period has been considered a time of increased risk for the development of psychiatric disorders with long-lasting adverse consequences. Psychoses are the most severe of these illnesses and can be resistant to psychiatric medication.
OBJECTIVE: We present two women with puerperal psychosis who had low serum estradiol, were refractory to neuroleptic medication but responded successfully to estradiol treatment.
METHODS: Serum estradiol concentration was measured at baseline and during the treatment with sublingual 17-beta estradiol. Treatment effect was evaluated using Brief Psychiatric Rating Scale.
RESULTS: Both patients had a low pretreatment estradiol concentration (28 and 54 pmol/l). During treatment with estradiol, the rise in serum estradiol coincided with a decline of psychotic symptoms. Discontinuation of estradiol treatment resulted in a rebound of florid psychotic symptoms in both cases.
CONCLUSIONS: Estradiol may have a causal relation to postpartum psychosis and significance in the treatment of this illness.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10591876     DOI: 10.1007/s002130051149

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  3 in total

Review 1.  Postpartum psychoses: prognosis, risk factors, and treatment.

Authors:  Bruno Pfuhlmann; Gerald Stoeber; Helmut Beckmann
Journal:  Curr Psychiatry Rep       Date:  2002-06       Impact factor: 5.285

2.  Amphetamine sensitization in reproductively experienced female rats.

Authors:  John J Byrnes; Robert S Bridges; Elizabeth M Byrnes
Journal:  Neurosci Lett       Date:  2011-07-30       Impact factor: 3.046

3.  Psychotic illness in first-time mothers with no previous psychiatric hospitalizations: a population-based study.

Authors:  Unnur Valdimarsdóttir; Christina M Hultman; Bernard Harlow; Sven Cnattingius; Pär Sparén
Journal:  PLoS Med       Date:  2009-02-10       Impact factor: 11.069

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.